CHRS Stock Overview A biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Coherus BioSciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Coherus BioSciences Historical stock prices Current Share Price US$1.52 52 Week High US$3.70 52 Week Low US$0.66 Beta 0.86 1 Month Change 39.45% 3 Month Change 46.15% 1 Year Change -24.75% 3 Year Change -91.45% 5 Year Change -91.65% Change since IPO -87.95%
Recent News & Updates See more updates
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise Dec 21
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development Dec 16
Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30% Nov 06
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive Sep 22
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects Aug 13
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S Aug 07
Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors Jun 06
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway May 31
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 24
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now May 23
Forecast breakeven date moved forward to 2024 May 12
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 10 Coherus BioSciences, Inc. announced that it has received $38.7 million in funding May 10
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer May 09
Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting Apr 24
Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024 Apr 16
Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded Mar 23
Coherus Biosciences: Dumping One Drug But Showing Promise With Another Mar 21
Forecast breakeven date pushed back to 2026 Mar 15
Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 06
New major risk - Financial position Feb 28
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 22
Lead Independent Director exercised options to buy US$139k worth of stock. Feb 07
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive Feb 03
Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million. Jan 23 Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million. Jan 22
Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium Jan 19
Coherus BioSciences: FDA Approvals Spice Up The Pipeline Jan 17
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Dec 27
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues Dec 20 Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer
Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023 Dec 08
Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress Dec 06
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29
Chairman notifies of intention to sell stock Nov 24
Consensus revenue estimates fall by 12% Nov 13
New major risk - Share price stability Nov 09
Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023 Nov 09
Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023 Nov 08
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 07
Price target increased by 7.3% to US$12.88 Nov 01 Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 16
Price target decreased by 7.6% to US$12.11 Oct 12
Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody Oct 06
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections Sep 26
Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others. Sep 09
New major risk - Share price stability Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Aug 03
Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors Jul 23
Coherus Launches Yusimry™, A Biosimilar of Humira® Jul 04 Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Price target decreased by 12% to US$13.63 Jun 17 Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 18
Price target decreased by 13% to US$15.56 May 17 Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 17
Consensus revenue estimates fall by 13% May 15
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically May 13
Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 10
Consensus EPS estimates upgraded to US$1.09 loss Apr 18
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 07
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 09
Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022 Sep 20
Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3 Sep 19
Coherus BioSciences, Inc. Announces Executive Changes Sep 10
Coherus: 2022 Is In Many Ways A Make Or Break Year Aug 24
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 05
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity Aug 03
Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli Aug 03
Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07 Shareholder Returns CHRS US Biotechs US Market 7D -5.6% -3.6% -2.4% 1Y -24.8% -2.6% 23.4%
See full shareholder returns
Return vs Industry: CHRS underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CHRS underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CHRS's price volatile compared to industry and market? CHRS volatility CHRS Average Weekly Movement 16.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CHRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHRS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
Show more Coherus BioSciences, Inc. Fundamentals Summary How do Coherus BioSciences's earnings and revenue compare to its market cap? CHRS fundamental statistics Market cap US$175.12m Earnings (TTM ) -US$450.00k Revenue (TTM ) US$304.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CHRS income statement (TTM ) Revenue US$304.34m Cost of Revenue US$168.26m Gross Profit US$136.08m Other Expenses US$136.53m Earnings -US$450.00k
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.0039 Gross Margin 44.71% Net Profit Margin -0.15% Debt/Equity Ratio -300.7%
How did CHRS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 11:06 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Coherus BioSciences, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Balaji Prasad Barclays Balaji Prasad Barclays
Show 14 more analysts 
